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Abstract:
Background: The aim of this study was to examine the effects of the hyperandrogenic state in dihydrotestosterone (DHT)-induced
polycystic ovary syndrome (PCOS), the vascular responses to different vasoactive agents, and the modulatory role of vitamin D3.
Methods: A PCOS model was induced by DHT application in 20 female Wistar rats. Ten of the DHT treated rats simultaneously re-
ceived calcitriol treatment. After 10 weeks, myographs were used to test the reactivity of isolated thoracic aortic rings to norepineph-
rine and acetylcholine. Thereafter, the vascular rings were incubated with the NO-synthase blocker (nitro-L-arginine methyl ester) or
the cyclooxygenase inhibitor (indomethacin) for 20 min, and the effects of norepinephrine and acetylcholine were re-evaluated.
Results: Norepinephrine-induced vasoconstriction was enhanced after DHT treatment, but this effect was attenuated by calcitriol
administration. Vasorelaxation of DHT-treated thoracic aortic rings was impaired, but this could be partly reversed by calcitriol ap-
plication. Impaired NO-dependent vasorelaxation in DHT-treated animals was mostly reversed by concomitant calcitriol admini-
stration, but this effect was diminished by prostanoid-dependent vasoconstriction.
Conclusions: These studies show that the enhanced sensitivity to vasoconstrictors and impaired NO-dependent vasorelaxation in
hyperandrogenic PCOS rats could be partially reversed by calcitriol treatment.
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Introduction
It has been shown that certain metabolic disorders
such as hyperinsulinemia, insulin resistance, meta-
bolic syndrome, diabetes mellitus and atherosclerosis
are characteristic defects in the majority of women
with polycystic ovary syndrome (PCOS) [5]. In the
present study, we examined early functional changes -
the earliest detectable lesions – of large vessels. Man-
neras et al. recently developed an adequate experi-
mental model to study PCOS [12]: chronic dihydro-
testosterone (DHT) application to adolescent female
rats induces a PCOS-like condition including early
dysfunction of carbohydrate homeostasis [12, 21].
Following this regimen of DHT treatment in rats, the
estrus cycle was not observed, but a threefold increase
in serum androgen levels, polycystic ovaries and insu-
linresistance were detected [12, 16, 21].
The protective effects of insulin sensitizers on
PCOS related vascular damage are well-known [1,
14], and vitamin D3 treatment has also been suggested
as an adjuvant therapy for PCOS [18]. Positive effects
of vitamin D3 therapy on carbohydrate metabolism [9]
and prevention of cardiovascular complications have
been reported [15, 20]. Therefore, we investigated the
effects of protective doses of calcitriol in hyperandro-
genic female (HAF) rats. Similar chronic calcitriol
therapies prevented heart failure and left ventricular
hypertrophy in adolescent heart failure-prone SHHF
rats [15]. In the present study, we aimed to clarify the
effects of DHT on norepinephrine-induced vasocon-
striction, acetylcholine (ACh)-induced NO-dependent
vasodilation and the possible protective effect of si-
multaneous calcitriol administration.
Materials and Methods
Drugs and Chemicals
Rats were anesthetized with pentobarbital for surgical
interventions (Nembutal, Phylaxia-Sanofi, Budapest,
Hungary). Our short preparation method for blood
pressure measurement did not require deep anesthesia
as a typical surgical preparation. We used anesthetics
only just below the pain reflex, which was assessed
through the cornea reflex. Following surgical inter-
ventions, 20 mg of amoxicillin and 4 mg of clavulanic
acid (Augmentin GlaxoSmithKline (Memphis, USA))
were dissolved in 0.2 ml saline, and this solution was
administered intramuscularly to prevent infections.
Experimental polycystic ovary syndrome was achie-
ved as described by Manneras et al. [12] by using
90-day continuous-release pellets containing 7.5 mg
dihydrotestosterone (Innovative Research of America,
Sarasota, FL, USA, daily dose: 83 µg). As an active
treatment, 1,25-(OH)2-D3 vitamin was used [15]
(calcitriol, Cacijex injections of 2 µg/ml, Abbott Labs.,
Illinois, USA). The normal Krebs-Ringer (nKR) solu-
tion used in the in vitro studies was composed of the
following (in mM): 119 NaCl, 4.7 KCl, 2.5 CaCl2
·2H2O, 1.17 MgSO4·7H2O, 20 NaHCO3, 1.18 KH2PO4,
0.027 EDTA, and 11 glucose (Sigma Aldrich Co., St.
Louis, MO, USA and Budapest, Hungary). The solu-
tion was kept at 37°C, and it was aerated with 5%
CO2 and 95% O2, which stabilized the pH at 7.4.
Norepinephrine, acetylcholine chloride, L-NG-nitro-
arginine methyl ester hydrochloride (L-NAME) and
indomethacin were obtained from Sigma-Aldrich Co.
(St. Louis, MO, USA and Budapest, Hungary). Drugs
were freshly prepared in nKR solution on the day of
the experiment.
Animals
Thirty adolescent, 21–28 day-old female Wistar rats
(Semmelweis University Animal Colony, Budapest,
Hungary originated from Charles River Ltd.) weigh-
ing 100–140 g were randomized into 3 treatment
groups. Twenty animals received subcutaneous pellets
of 7.5 mg dihydrotestosterone (DHT) underneath the
back skin under anesthesia (induced with Nembutal at
45 mg/kg) and under sterile conditions. Ten animals
underwent sham operations (referred to as the sham
group). Ten DHT animals received 120 ng/100 g body
weight/week of 1,25-(OH)2-D3 vitamin subcutane-
ously(DHT + D3 group), as previously described by
Przybylski et al. [15]. We applied one weekly dosage
instead of daily administration [15], to reduce stress
to the animals. The sham group and 10 DHT animals
received the calcitriol vehicle (DHT + saline group).
No medical or surgical complications were observed.
Conventional rat chow and tap water were provided
ad libitum. The investigation conformed to the Guide
for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health and was
approved by the Institutional Animal Care Commis-
sion (IRB approval: 22.1/2960/003/2009).
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Invivo blood pressure measurement
Ten weeks after DHT pellet application, blood pres-
sure was measured directly through the carotid artery
in anesthetized rats (Nembutal 45 mg/kg im) with
a Statham transducer connected to a Cardiosys
CO-104 system (Experimetria, Budapest, Hungary).
Ex vivo pharmacological reactivity of thoracic
aortic rings
After opening of the chest, the anesthetized animals
were perfused transcardially with 10 ml of hepar-
inized (10 IU/ml) nKR solution. After perfusion, each
animal’s aorta was removed. The distal part of the
thoracic aorta (TA) was isolated, and four rings were
prepared and placed into a vessel chamber filled with
nKR solution aerated with carbogen (95% O2 bal-
anced with 5% CO2, Lindegas, Répcelak, Hungary).
Thoracic aorta (TA) segments of 3 mm length from
each experimental group were mounted on stainless
steel vessel holders (200 µm in diameter) of a conven-
tional myograph setup (610-M Multi Myograph Sys-
tem; Danish Myo Technology, Aarhus, Denmark).
The organ chambers of the myographs were filled
with 8 ml of nKR solution. The bath was warmed to
37°C, and the resting tension of the TA rings was ad-
justed to 15 mN, according to previous studies [3, 7].
Segments were exposed to 124 mM K+ to elicit a ref-
erence contraction. After recovery, norepinephrine (109 –
106 M) and acetylcholine (108 – 105 M) dose-response
curves were recorded. Thereafter, the vascular rings were
incubated with either 104 M indomethacin or 104 M
L-NAME for 20 min, and norepinephrine and ACh
dose-response measurements were repeated to test differ-
ent potential pathways of relaxation. Between measure-
ments, the vessels were rinsed and allowed to recover for
20 min. Norepinephrine contraction was expressed as
a percentage of K+-precontraction. Aortic relaxations
were tested after a stable plateau of contraction had been
reached. Relaxant responses were expressed as a percent-
age of the precontraction induced by norepinephrine.
The isometric tension recording of the thoracic
aorta segments was made with the MP100 system,
and recorded data were analyzed with Acknowledge
3.7.3 software (BIOPAC Systems, Goleta, CA). Va-
soactive substances were dissolved in physiological
saline solution (0.9% w/v NaCl). All concentrations
are expressed as the final concentration in the organ
bath.
Histology
Ovaries and aortic rings of the animals were collected
and freshly fixed for histological examinations. Tis-
sue samples were immersion-fixed in 4% buffered
formaldehyde and examined by light microscopy [he-
matoxylin and eosin staining; for evaluation Pano-
ramic viewer software was used (3DHISTECH Ltd.,
Budapest, Hungary)]. Ovaries were examined for evi-
dence of polycystic morphology, as described previ-
ously [16]. The results are shown in Figure 1 A (sham)
and B (DHT treated).
Statistical analysis
Following normality tests (F-tests), dose-tension
curves were statistically analyzed by a repeated meas-
ures ANOVA test and discrete parameters (e.g., body
weights) were analyzed by one-way ANOVA tests.
The Newman-Keuls test was applied as a post-hoc
test; p < 0.05 was uniformly accepted as a significant
difference. Data are presented as the mean ± SEM.
Results
The mean arterial pressure was 122 ± 3 mmHg, 123
± 6 mmHg and 123 ± 4 mmHg in the sham, DHT
+ saline and DHT + D3 groups, respectively. Body
weights at the end of the study were: 298 ± 8 g, 354
± 16 g and 353 ± 9 g in the 3 groups, respectively.
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Fig. 1. Ovarian morphology following DHT treatment. Panel A shows
the sham, and Panel B shows DHT-treated ovaries
Body weights of the DHT-treated animals differed
significantly (p < 0.05) from those of the sham treated
group, but not from each other (DHT + saline vs. DHT
+ D3, not significant)
The histology results showed a similar morphology
in the aorta for each of the 3 groups. Aorta wall thick-
ness values were not significantly different: 113 ± 4 µm
(sham), 122 ± 5 µm (DHT + saline) and 113 ± 6 µm
(DHT +D3).
Vasoconstrictor responses
The reference contractions of aortic rings exposed to
124 mM K+ were similar and not significantly differ-
ent in all 3 groups: 26.1 ± 0.4 mN (sham), 26.6 ± 0.5 mN
(DHT + saline) and 25.7 ± 0.5 mN (DHT + D3).
Norepinephrine contractions applied in a cumula-
tive dose response manner were augmented signifi-
cantly in the DHT-treated aortas compared to sham
(p < 0.05). 1,25-(OH)2-D3 vitamin (calcitriol) treat-
ment diminished the difference compared to sham.
The DHT + D3 group did not significantly differ from
the DHT + saline or the sham group (Fig. 2).
Contractions in response to norepinephrine under
L-NAME pre-incubation increased significantly (p <
0.0001) in aortas of DHT animals. Calcitriol treat-
ment (DHT + D3 group) partially reduced this con-
tractility enhancement, with the results significantly
differing from both the DHT + saline and the sham re-
sults (p < 0.05) (Fig. 3).
Following indomethacin incubation, there was
a significant difference between the aortas of the
sham and the DHT animals throughout the entire dose
range (p < 0.05), with stronger contractions in the
DHT animals. Calcitriol treatment significantly inhib-
ited contractility-enhancement at small norepineph-
rine doses (109 – 108 M), but had no effect at higher
norepinephrine doses. At low norepinephrine concen-
trations the DHT + D3 curve approached the sham
curve and differed significantly from the DHT + sa-
line (p < 0.05) data, whereas at high norepinephrine
concentrations the DHT + D3 curve was similar to the
DHT + saline curve, with both groups differing sig-
nificantly (p < 0.05) from the sham (Fig. 4).
Vasorelaxation
Following the pre-contraction of the aortic rings in-
duced by 106 M norepinephrine, acetylcholine
(ACh)-induced relaxation was determined. Cumula-
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Fig. 2. Norepinephrine contraction of the vessels. The line graphs de-
pict the contraction-response curves of aortic rings to increasing
doses of 109 – 106 M norepinephrine for three groups: sham, dihy-
drotestosterone and dihydrotestosterone plus D3 vitamin treated
rats. The y axis shows contractions and the x axis shows norepineph-
rine concentrations. Each data point represents the mean ± SEM.
Dihydrotestosterone-enhanced contractions (sham vs. DHT, * p <
0.05), and calcitriol reduced the responses to the levels of the sham
group (non-significant for sham vs. DHT + D3 and DHT vs. DHT + D3)
Fig. 3. Norepinephrine contractions under L-NAME incubation. Line
graphs show the contraction response curves of aortic rings to in-
creasing doses of norepinephrine (109 – 106 M) following L-NAME
incubation. Each data point represents the mean values ± SEM. DHT
enhanced contraction capacity (sham vs. DHT + saline, * p <
0.0001), but simultaneous calcitriol treatment partly reduced the
contractility-enhancement due to DHT († p < 0.05 sham vs. DHT +
D3, ‡ p < 0.05 DHT vs. DHT + D3)
tive dose-response curves of the sham group were sig-
nificantly different from both the DHT-saline and
DHT-D3 groups throughout the entire dose range from
108 to105 M.
After pre-contraction by 106 M norepinephrine,
the cumulative dose-response curves (108 – 105 M)
of acetylcholine-induced relaxation demonstrated that
the sham group differed from both DHT + saline and
DHT + D3 treated groups (p < 0.05 for both compari-
sons) in the entire dose range. However, at higher
doses of ACh, the relaxation of the DHT + D3 group
was significantly larger than that of the DHT + saline
group (Fig. 5).
After L-NAME incubation (Fig. 6), significant differ-
ences were detected in ACh-relaxation over the entire
measurement range between the DHT + saline group
and the other two groups (sham and DHT + D3 treated
rats) (p < 0.05, Fig. 6). Calcitriol normalized the ACh-
induced relaxation because there was no difference be-
tween the sham- and DHT + D3-treated groups.
A comparison of the ACh-induced relaxation of the
experimental groups after indomethacin incubation
showed that the three curves were practically identical
(without any significant differences) throughout the
entire dose range (Fig. 7).
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Fig. 4. Norepinephrine contractions under indomethacin incuba-
tion. Line graphs show the contraction response curves of aortic
rings to increasing doses of norepinephrine (109 – 106 M) after
indomethacin incubation. Contractions of aortas of DHT-treated rats
exceeded sham rats within the entire dose range (sham vs. DHT
+ saline, * p < 0.05). Administration of calcitriol at low doses (108 M)
of norepinephrine had a protective effect (‡ = p < 0.05 DHT vs. DHT
+ D3, and not significant for sham vs. DHT + D3). This protective ef-
fect of calcitriol was absent at higher (107 – 106 M) norepinephrine
concentrations († p < 0.05 sham vs. DHT + D3, and not significant for
DHT vs. DHT + D3)
Fig. 5. Acetylcholine relaxation. Following norepinephrine (106 M)
pre-contraction, cumulative doses of ACh (108 – 105 M) induced
dose dependent relaxations. Within the entire dose range of ACh,
only the sham group differed significantly from both the DHT + saline
(* p < 0.05) and the DHT + D3 († p < 0.05) treated groups. However,
at higher doses of ACh, 106 – 105M, calcitriol (DHT + D3) enhanced
relaxation significantly compared to DHT + saline (‡ p < 0.05)
Fig. 6. Acetylcholine relaxation after L-NAME pre-incubation. Follow-
ing L-NAME incubation, significant differences were measured in
ACh-relaxation throughout the entire measurement range between
the DHT + saline group and both the sham (* p < 0.05) and the DHT
+ D3 (‡ p < 0.05) groups. There was no difference between the sham
and the DHT + D3 treated groups
Discussion
In this study, we have, for the first time, demonstrated
early changes in conduit vessel function and quanti-
fied the effects of parallel 1,25-(OH)2-D3 vitamin
(calcitriol) therapyin a rat PCOS model.
In a DHT-induced hyperandrogenic state, nor-
adrenaline-induced contractions of rat aortas were en-
hanced. This effect was diminished by simultaneous
calcitriol therapy (Fig. 2).
ACh-induced relaxation was more intense in the
aortas of sham treated animals than in the two DHT
groups (Fig. 5). ACh relaxation was decreased in
DHT animals and calcitriol treatment did not return
relaxation values to those of the sham group. How-
ever, following incubation with L-NAME, aortic rings
of the DHT groups remained more contracted, and
calcitriol-treatment enhanced relaxation significantly
enough to return the DHT + D3 group to sham levels
(Fig. 6).
Indomethacin incubation diminished tone differ-
ences of the treatment groups. We assume that ACh-
dependent relaxation differences contribute to
prostanoid-dependent vascular effects, such as altered
constrictor/dilator prostanoid balance (Fig. 7).
Increasing NO release is counterbalanced by con-
strictor prostanoids in the aortic rings of DHT + cal-
citriol treated animals during ACh-relaxation.
The rat model we used in our experiments is an ap-
proved model of PCOS [12, 21]. Eight to 12 weeks
after similar DHT application, rat ovaries developed
polycystic deformations, as well as significantly higher
androgen levels [12]. In this model, during the course
of 90 days of DHT application, Yanes detected nu-
merous metabolic changes [21] such as insulin resis-
tance [16, 21], higher cholesterol levels and greater
oxidative stress [21]. These metabolic changes can in-
fluence the pharmacological responsiveness of blood
vessels as well.
Longer term (90 days) DHT application, as in the
aforementioned experiment, caused hypertension as
well, while in our 70-day treatment blood pressure
changes were not observed among the studied ani-
mals. The increased contractility in an already nor-
motensive state, as well as the lower ACh-related re-
laxation capacity can be considered prehypertensive
changes, similar to those found by Keller et al. on
mesenteric arteries in hypertension following a 90-
day regimen [8]. In the present study, we found a high
degree of depletion of relaxation reserves, which can
be a self-boosting local factor of the development of
hypertension. The partial-compensation experienced
in rats treated with vitamin D3 has a local effect
against the development of high blood pressure. How-
ever, in response to long term pressor effects, the anti-
hypertensive impact of calcitriol treatment dimin-
ished.
Because the blood pressures of the animals in our
study did not differ significantly from each other, the
detected changes in the pharmacological reactivity of
aortas should be considered as consequences of either
the hyperandrogenic state or of insulin resistance, as
our research team has previously demonstrated using
this model [16]. In women with PCOS, significant
pharmacological reactivity changes develop, as well
as mechanical damage to the large blood vessels [5,
11]. Changes in smooth muscle and endothelial-
related relaxation, as well as vasoconstriction, were
studied in PCOS and under hyperandrogenic circum-
stances: Kravariti measured a significant decrease in
both endothelial-dependent and smooth muscle-
related (nitrate-mediated) relaxation [10]. The degree
of insulin resistance, the level of the hyperandrogenic
state and cholesterol levels were all independent fac-
tors related to diminished flow. It has been suggested
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Fig. 7. Acetylcholine relaxation after indomethacin pre-incubation.
ACh-induced relaxation was measured as a percentage of contrac-
tion induced by 106 M norepinephrine following indomethacin incu-
bation. The groups did not significantly differ from each other
throughout the entire dose range
that in women with PCOS, endothelial dysfunction is
present from their twenties onward, independently of
obesitylevels [10].
Flow-dependent dilation has been studied by nu-
merous groups, all of which found non-significant dif-
ferences between PCOS patients and healthy indi-
viduals [2, 17]. The apparent contradiction is resolved
by Cussons’ data which points to gradual damage.
Cussons described a decrease in flow-mediated vaso-
dilation at a physiological arterial stiffness as the
earliest detectable change [4]. In conclusion, early
(possibly when the patient is in their 20s and 30s) and
gradual development of initial changes may be the
first steps to hypertension and metabolic syndrome
[4].
The pharmacological responsiveness to PCOS ther-
apy is a subject of intense research. Agarwal demon-
strated that metformin treatment reduced arterial stiff-
ness, aortic and brachial pulse wave velocities, and
the aortic augmentation index, but it also improved
endothelium-dependent and independent vascular re-
sponses and endothelial function [1]. During insulin-
sensitizer therapy, either metformin or pioglitazone
caused enhancement of flow-mediated vasodilation in
PCOS women [14]. The therapies used to treat PCOS
have been found to alter cardiovascular risk [1, 13].
Contraceptives containing high hormone levels may
increase cardiovascular risk, while metformin treat-
ment decreases cardiovascular risk [13]. However,
small doses of contraceptives are not likely to influ-
ence cardiovascular risk substantially [1, 2]. Vitamin
D is an accepted adjuvant therapy in PCOS [18] and it
was described that in small doses it has a cardiovascu-
lar protective effect [15, 20]. However, there has been
no information on the effects of vitamin D and its’ ac-
tive form, calcitriol on vascular adaptation and phar-
macological responsiveness to constrictor and vasodi-
lator stimuli on large blood vessels in PCOS. Earlier,
Weishaar and Simpson described an enhanced vaso-
constriction of aortic rings in vitamin D deficient
male rats [19], which was reversible following vita-
min D3 replacement. This effect was time and dose
dependent – occurred following nine weeks of treat-
ment and was not measured following six weeks [19].
We measured similar increase in the contractility of
aortic rings in hyperandrogenic female rats, which was
balanced by a longer (ten weeks) calcitriol treatment.
An important implication of our study is that vitamin
D3, applied as an adjuvant treatment in PCOS, can de-
lay the development of prehypertensive-induced dam-
age on large blood vessels and may potentiate the vas-
cular protective effects of metformin. Other vitamins
might also have positive vascular effects in glucose
imbalance on androgen dependent vascular function
as demonstrated by Fernandes et al. [6].
DHT treatment lowered norepinephrine-induced
contraction and reduced acetylcholine- as well as
insulin-induced dilation of resistance vessels. Cal-
citriol treatment restored insulin relaxation and
norepinephrine-induced contractility; however, it
failed to alter NO dependent relaxation [16]. On small
and large arteries we found similarities and differ-
ences in vascular reactivity. This finding could ex-
plain the different effects of vasorelaxants on the aorta
and on arterioles.
In the present study, we demonstrated for the first
time that in a rat model of PCOS enhanced contrac-
tions in response to norepinephrine can be partly
counter-balanced by simultaneous therapy with cal-
citriol. We also demonstrated that acetylcholine-
dependent vasorelaxation was not affected by cal-
citriol, most likely due to a constrictor-prostanoid ef-
fect, which mainly neutralized the enhanced NO-
dependent relaxation. According to our results, the
hyperandrogenic state resulted in prehypertensive
blood vessel changes, and the depletion of vasorelax-
ant reserves. Calcitriol treatment reversed the vaso-
constrictor reactivity that was elevated by DHT ad-
ministration, and partially counter-balanced the pre-
hypertensive changes of the aorta.
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